glp-1 news today november 2025 updates FDA bans compounded drugs glp-1 news 2025 november Shortage – GLP-1 drugs can be ‘too

The phase 3b trial, led by Weill Cornell Medicine and NewYork-Presbyterian, enrolled patients from the SURMOUNT-5 study and represents the first head-to-head data on longer-term weight maintenance using an oral GLP-1 following injectable therapy

Potential risks : Unknown long-term effects and quality control issues with compounded peptides pose serious concerns

Semaglutide is also available as a once-daily oral capsule (Rybelsus) for the treatment of diabetes

Meanwhile, hypoxia results in excessive production of intracellular reactive oxygen species (ROS), which in turn cause oxidative injury in tissues [7], endoplasmic reticulum (ER) stress [8], autophagy and apoptosis [9]